Effect of Nicergoline on Vertigo and Tinnitus.

Akisada, Takeshi; Orita, Yozo; Sato, Yukihiro; Handa, Toru; Yada, Kazuko; Kawai, Akimitsu; Takemoto, Takuji; Oku, Masaya

doi:10.5631/jibirin.87.845

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, where approved, nicergoline is being used as follows: to improve the apathy and affective disorders caused by cerebral infarction (such as reduced mental alertness, inattention, impairment of recent memory, hypobulia, and depression); in the treatment of acute and chronic peripheral circulation disorders (such as obliterative vascular disease of the limbs, Raynaud's syndrome, and other peripheral circulation dysfunction symptoms); in the treatment of vascular dementia, especially for the improvement in cognitive dysfunction and memory and to reduce the severity of this disease. In addition, studies have reported the usefulness of nicergoline in posthemodialysis pruritus [ 29 ], tinnitus and vertigo [ 30 ], and ocular conditions such as arterial obstructions, venous thrombosis, diabetic retinopathies, senile macular degenerations, papilla ischaemic oedema, central serous chorioretinopathies, and glaucoma [ 31 ]. It has also displayed efficacy in the prevention of postoperative thrombophlebitis [ 32 ], management of balance disorders of central origin, Parkinson's disease, Leukoaraiosis, and benign prostatic hyperplasia [ 3 ].…”

Section: Uses Of Nicergolinementioning

confidence: 99%

Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders

Saletu

Garg

Shoeb

2014

BioMed Research International

View full text Add to dashboard Cite

Nicergoline is a semisynthetic ergot derivative and has a selective alpha-1A adrenergic receptor blocking property and also other additional mechanisms of actions, both in the brain and in the periphery. It is in clinical use for over three decades in over fifty countries for conditions such as cerebral infarction, acute and chronic peripheral circulation disorders, vascular dementia, and Alzheimer's disease and has been found to be beneficial in a variety of other conditions. However, concerns about its safety have been raised, especially after the European medicines agency's (EMEA's) restriction in the use of all ergot derivatives including nicergoline. But, most of the available literature and data suggest that the adverse events with nicergoline are mild and transient. Further, none of the available treatment options for cognitive disorders afford definitive resolution of symptoms. In this backdrop, we discuss the pharmacology of nicergoline with special emphasis on the safety of this compound, especially when used in patients suffering from cognitive function disorders.

show abstract

Section: Uses Of Nicergolinementioning

confidence: 99%

Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders

Saletu

Garg

Shoeb

2014

BioMed Research International

View full text Add to dashboard Cite

show abstract

“… 1 32 Also, nicergoline has shown efficacy in conditions like posthaemodialysis pruritus, 39 tinnitus and vertigo. 40 Nicergoline has a positive effect on cognition and behaviour in addition to an effect on clinical global impression in older patients with mild-to-moderate cognitive and behavioural impairment of various clinical origins including chronic cerebrovascular disorders and Alzheimer's dementia. 1 …”

Section: Discussionmentioning

confidence: 99%

A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline

Fioravanti¹,

Nakashima²,

Xu³

et al. 2014

BMJ Open

View full text Add to dashboard Cite

ObjectiveTo evaluate the safety profile of nicergoline compared with placebo and other active agents from published randomised controlled trials.DesignSystematic review and meta-analysis of nicergoline compared with placebo and other active agents across various indications.Data sourcesMEDLINE, Medline-in-process, Cochrane, EMBASE, EMBASE alerts, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR) and Cochrane Methodology Register (CMR) for all the randomised controlled trials, open-label or blinded, in adults treated with nicergoline. Studies published until August 2013 were included.Review method29 studies were included for data extraction. The studies included in this review were majorly from European countries and mostly in cerebrovascular disease (n=15) and dementia (n=8).ResultsThe treatment withdrawals were comparatively lower in the nicergoline group as compared with the placebo group (RR=0.92; 95% CI 0.7 to 1.21) and other active comparators (RR=0.45; 95% CI 0.10 to 1.95), but the difference was non-significant. Incidence of any adverse events (AEs) was slightly higher (RR=1.05; 95% CI 0.93 to 1.2) while incidence of serious AEs was lower (RR=0.85; 95% CI 0.50 to 1.45) in the nicergoline compared with placebo group. Frequency of anxiety was significantly lower in nicergoline as compared with placebo (p=0.01). Other AEs including diarrhoea, gastric upset, dizziness and drowsiness were less frequent in the nicergoline group when compared with placebo/active drugs, but the difference was non-significant. Frequency of hypotension and hot flushes was slightly higher in the nicergoline group but the difference was non-significant. None of the studies reported any incidence of fibrosis or ergotism with nicergoline treatment.ConclusionsNicergoline is an ergot derivative, but its safety profile is better than other ergot derivatives like ergotamine and ergotoxine. This systematic review and meta-analysis suggests that nicergoline has a good safety profile. None of the studies included in this systematic review reported any incidence of fibrosis or ergotism with nicergoline.

show abstract

Pharmacoepigenetics of Vertigo and Related Vestibular Syndromes

Guerra

Cacabelos

2019

Pharmacoepigenetics

View full text Add to dashboard Cite

Effect of Nicergoline on Vertigo and Tinnitus.

Cited by 4 publications

References 0 publications

Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders

Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders

A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline

Pharmacoepigenetics of Vertigo and Related Vestibular Syndromes

Contact Info

Product

Resources

About